Advertisement
The seminar will be held in New York, N.Y. on September 14, 2010 and will answer the following questions:
"Developments in the biologics and biosimilars markets are constantly evolving and present significant opportunities, as well as potential challenges, for pharmaceutical manufacturers," said Decision Resources Chief Operating Officer Jason LaBonte. "This high-value seminar is geared toward both manufacturers already operating in the biologics and biosimilars markets, as well as companies exploring market opportunities in this space. Attendees will leave with an understanding of the current trends in biologics and biosimilars and how these trends will shape future opportunities."
Advertisement
Presentation topics include:
For more information about registration and to view the meeting agenda, please visit: http://www.competitivelandscapeseries.com/biologics-and-biosimilars/.
Media Invitation
Members of the media interested in receiving an invitation to the Decision Resources' Competitive Landscape Seminar Series: Biologics and Biosimilars should contact Lisa Osgood at 781-296-2606 or by e-mail at [email protected].
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
-- Who are the key players in the biologics market and who will see the greatest growth? -- Which companies are in the best position to produce biosimilars? -- How quickly will biologics saturate niche markets? -- What are the current and future prospects for biologics in the emerging markets? -- How are payers influencing the biologics market in the United States? -- What opportunities and challenges lie ahead for agents in specific therapeutic areas such as immune and oncology?
SOURCE Decision Resources
